Aclaris Therapeutics (ACRS) EBT Margin Growth (5y) (2022 - 2026)
Powered by 
Analysis
Aclaris Therapeutics (ACRS) EBT Margin Growth (5y) (2022 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.78 Bn | 130.92 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.50 Bn | 77.51 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn |
| 4 | Moderna | 58.06 Bn | 52.92 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.04 Bn | 44.04 Bn | - |
| 6 | BeOne Medicines | 40.04 Bn | 34.94 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.45 Bn | 32.14 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.41 Bn | 27.57 Bn | - |
| 9 | Insmed | 27.42 Bn | 26.26 Bn | 358.27 Mn |
| 10 | Aclaris Therapeutics | 878.55 Mn | 878.55 Mn | 1.41 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -39,400.00 |
| Mar 31, 2026 | 57,146.00 |
| Dec 31, 2025 | -77,105.00 |
| Sep 30, 2025 | 25,919.00 |
| Jun 30, 2025 | -36,428.00 |
| Mar 31, 2025 | 378.00 |
| Dec 31, 2024 | 54,490.00 |
| Sep 30, 2024 | 213,316.00 |
| Jun 30, 2024 | 452,043.00 |
| Mar 31, 2024 | 143,265.00 |
| Dec 31, 2023 | 64,383.00 |
| Sep 30, 2023 | 158,789.00 |
| Jun 30, 2023 | -87,586.00 |
| Mar 31, 2023 | 161,199.00 |
| Dec 31, 2022 | 38,381.00 |
| Sep 30, 2022 | 262,240.00 |